Literature DB >> 22133117

How novel molecular diagnostic technologies and biomarkers are revolutionizing genetic testing and patient care.

Linnea M Baudhuin1, Leslie J Donato, Timothy S Uphoff.   

Abstract

Technological applications and novel biomarkers in the field of molecular diagnostics have never been evolving at a more rapid pace. These novel applications have the promise to change the face of clinical care as we move into the era of personalized medicine. While some of these technologies and biomarkers have been adopted by some clinical laboratories, most laboratories face a steep learning curve in bringing these dramatically new and different molecular diagnostic applications on board. Furthermore, interpreting the vast amounts and new types of data produced by these novel applications brings forth challenges for laboratorians and clinicians alike. In this article, we discuss how some of these emerging novel molecular diagnostic technologies and analytes, such as next-generation sequencing, chromosomal microarray, microRNAs and circulating fetal nucleic acids are revolutionizing patient care and personalized medicine.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22133117     DOI: 10.1586/erm.11.85

Source DB:  PubMed          Journal:  Expert Rev Mol Diagn        ISSN: 1473-7159            Impact factor:   5.225


  10 in total

1.  Detection of EGFR and BRAF mutations by competitive allele-specific TaqMan polymerase chain reaction in lung adenocarcinoma.

Authors:  Yang Yang; Yi Meng; Hang Zhang; Xiaoyan Shen; Rutian Li; Lixia Yu; Baorui Liu; Lifeng Wang
Journal:  Oncol Lett       Date:  2017-12-19       Impact factor: 2.967

Review 2.  How many molecular subtypes? Implications of the unique tumor principle in personalized medicine.

Authors:  Shuji Ogino; Charles S Fuchs; Edward Giovannucci
Journal:  Expert Rev Mol Diagn       Date:  2012-07       Impact factor: 5.225

3.  Managing Expectational Language: Translational genetic professionals consider the clinical potential of next-generation sequencing technologies.

Authors:  Pei P Koay; Richard R Sharp
Journal:  New Genet Soc       Date:  2014-06-01

4.  Preferences for results delivery from exome sequencing/genome sequencing.

Authors:  Martha F Wright; Katie L Lewis; Tyler C Fisher; Gillian W Hooker; Toby E Emanuel; Leslie G Biesecker; Barbara B Biesecker
Journal:  Genet Med       Date:  2013-12-05       Impact factor: 8.822

5.  Transparency of reporting in molecular diagnostics.

Authors:  Stephen Bustin
Journal:  Int J Mol Sci       Date:  2013-07-30       Impact factor: 5.923

Review 6.  Molecular pathological epidemiology in diabetes mellitus and risk of hepatocellular carcinoma.

Authors:  Chun Gao
Journal:  World J Hepatol       Date:  2016-09-28

Review 7.  Approaches and genetic determinants in predicting response to neoadjuvant chemotherapy in locally advanced gastric cancer.

Authors:  Jichun Zhou; Jianguo Shen; Benjamin J Seifer; Shaojie Jiang; Ji Wang; Hanchu Xiong; Lingmin Xie; Linbo Wang; Xinbing Sui
Journal:  Oncotarget       Date:  2017-05-02

8.  Clinical significance of UGT1A1 polymorphism and expression of ERCC1, BRCA1, TYMS, RRM1, TUBB3, STMN1 and TOP2A in gastric cancer.

Authors:  Yongkuan Cao; Guohu Zhang; Peihong Wang; Jun Zhou; Wei Gan; Yaning Song; Ling Huang; Ya Zhang; Guode Luo; Jiaqing Gong; Lin Zhang
Journal:  BMC Gastroenterol       Date:  2017-01-05       Impact factor: 3.067

Review 9.  Diagnosis, monitoring and prevention of exposure-related non-communicable diseases in the living and working environment: DiMoPEx-project is designed to determine the impacts of environmental exposure on human health.

Authors:  Lygia Therese Budnik; Balazs Adam; Maria Albin; Barbara Banelli; Xaver Baur; Fiorella Belpoggi; Claudia Bolognesi; Karin Broberg; Per Gustavsson; Thomas Göen; Axel Fischer; Dorota Jarosinska; Fabiana Manservisi; Richard O'Kennedy; Johan Øvrevik; Elizabet Paunovic; Beate Ritz; Paul T J Scheepers; Vivi Schlünssen; Heidi Schwarzenbach; Per E Schwarze; Orla Sheils; Torben Sigsgaard; Karel Van Damme; Ludwine Casteleyn
Journal:  J Occup Med Toxicol       Date:  2018-02-05       Impact factor: 2.646

10.  Online direct-to-consumer messages about non-invasive prenatal genetic testing.

Authors:  Ruth M Farrell; Patricia K Agatisa; MaryBeth Mercer; Marissa B Coleridge
Journal:  Reprod Biomed Soc Online       Date:  2016-03-10
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.